The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05137236
Recruitment Status : Completed
First Posted : November 30, 2021
Last Update Posted : March 21, 2024
Sponsor:
Information provided by (Responsible Party):
ModernaTX, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The main goal of Part A of this study is to assess the safety, reactogenicity, and immunogenicity of the study vaccine candidates. The main goal of Part B of this study is to assess the safety, reactogenicity, and immunogenicity of the mRNA-1283.529 booster vaccine candidate.

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Biological: mRNA-1283 Biological: mRNA-1283.211 Biological: mRNA-1273 Biological: mRNA-1283.529 Phase 2

Detailed Description:

Part A of this study will assess whether a single dose of mRNA-1283 at three different dose levels or mRNA-1283.211 at two different dose levels will boost antibody responses to the Wuhan-Hu-1 (ancestral strain of SARS-CoV-2) virus, and to the B.1.351 variant, and potentially other SARS-CoV-2 variants, and it will also be used to select a dose for subsequent clinical evaluation. The study will include an active comparator group of participants who will receive mRNA-1273.

Participants in Part A who received the primary series of mRNA-1273 with appropriate documentation at least 6 months prior will be randomized 1:1:1:1:1:1 to receive a single boost of mRNA-1283 at one of three dose levels, a single boost of mRNA-1283.211 at one of two dose levels, or a single dose of the active comparator, mRNA-1273.

Part B of this study will assess whether a single dose of mRNA-1283.529 at two different dose levels as the second booster after a first booster of mRNA- 1273, at least 3 months prior, will boost antibody response to the ancestral strain of the SARS-CoV-2 virus, the B.1.1.529 variant, and potentially other SARS-CoV-2 variants, and inform dose selection for mRNA-1283.529 booster vaccine candidate for subsequent clinical evaluation.

Participants in Part B who received the primary series of mRNA 1273 and who received a first booster dose of mRNA-1273 at least 3 months prior will be enrolled in a 1:1 ratio to receive a single boost of mRNA 1283.529 at one of two dose levels.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 540 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Part A of this study is designed as an observer-blind study. Part B of the study is designed as an open-label study.
Primary Purpose: Prevention
Official Title: A Phase 2A, Randomized, Stratified, Observer-Blind Study to Evaluate the Immunogenicity and Safety of mRNA-1283 Vaccine Boosters for SARS-CoV-2
Actual Study Start Date : December 6, 2021
Actual Primary Completion Date : March 23, 2023
Actual Study Completion Date : March 23, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Part A: mRNA-1283 Dose Level 1
Participants will receive single intramuscular (IM) injection of mRNA-1283 at Dose Level 1 on Day 1.
 Biological: mRNA-1283
Sterile liquid for injection
Experimental: Part A: mRNA-1283 Dose Level 2
Participants will receive single IM injection of mRNA-1283 at Dose Level 2 on Day 1.
 Biological: mRNA-1283
Sterile liquid for injection
Experimental: Part A: mRNA-1283 Dose Level 3
Participants will receive single IM injection of mRNA-1283 at Dose Level 3 on Day 1.
 Biological: mRNA-1283
Sterile liquid for injection
Experimental: Part A: mRNA-1283.211 Dose Level 1
Participants will receive single IM injection of mRNA-1283.211 at Dose Level 1 on Day 1.
 Biological: mRNA-1283.211
Sterile liquid for injection
Experimental: Part A: mRNA-1283.211 Dose Level 2
Participants will receive single IM injection of mRNA-1283.211 at Dose Level 2 on Day 1.
 Biological: mRNA-1283.211
Sterile liquid for injection
Active Comparator: Part A: mRNA-1273
Participants will receive single IM injection of mRNA-1273 on Day 1.
 Biological: mRNA-1273
Sterile liquid for injection
Experimental: Part B: mRNA-1283.529 Dose Level 1
Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 1 on Day 1.
 Biological: mRNA-1283.529
Sterile liquid for injection
Experimental: Part B: mRNA-1283.529 Dose Level 2
Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 2 on Day 1.
 Biological: mRNA-1283.529
Sterile liquid for injection


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Parts A and B: Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) [ Time Frame: Up to Day 7 (7-day follow-up after vaccination) ]
  2. Parts A and B: Number of Participants with Unsolicited Adverse Events (AEs) [ Time Frame: Up to Day 28 (28-day follow-up after vaccination) ]
  3. Parts A and B: Number of Participants with Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study, and AEs of Special Interest (AESIs) [ Time Frame: Day 1 to end of study (EOS) (Day 366) ]
  4. Part A: Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29 [ Time Frame: Day 29 ]
  5. Part A: GMT of SARS-CoV-2 Specific Binding Antibody (bAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29 [ Time Frame: Day 29 ]
  6. Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29 [ Time Frame: Day 29 ]
  7. Part B: GMT of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29 [ Time Frame: Day 29 ]
  8. Part A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29 [ Time Frame: Day 29 ]
  9. Part A: GMFR of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29 [ Time Frame: Day 29 ]
  10. Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29 [ Time Frame: Day 29 ]
  11. Part B: GMFR of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29 [ Time Frame: Day 29 ]
  12. Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Day 29 [ Time Frame: Day 29 ]
  13. Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Day 29 [ Time Frame: Day 29 ]

Secondary Outcome Measures :
  1. Part A: GMT of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]
  2. Part A: GMT of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]
  3. Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]
  4. Part B: GMT of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]
  5. Part A: GMFR of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]
  6. Part A: GMFR of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]
  7. Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]
  8. Part B: GMFR of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]
  9. Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variants, Including B.1.351 at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]
  10. Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529) at Days 1, 15, 29, 181, and 366 [ Time Frame: Days 1, 15, 29, 90, 181, and 366 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as bilateral tubal ligation >1 year prior to screening, bilateral oophorectomy, hysterectomy, or menopause.
  • Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of vaccination (Day 1), practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreed to continue adequate contraception through 3 months following the last vaccine administration, and not currently breastfeeding.
  • Participant must have received their second dose of the mRNA-1273 primary series at least 6 months prior to screening and enrollment (Part A) or have received the mRNA-1273 series and an mRNA-1273 booster dose at least 3 months prior to screening and enrollment (Part B).

Exclusion Criteria:

  • Had significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 14 days, defined by the US Centers for Disease Control and Prevention (CDC) as a close contact of someone who has COVID-19.
  • Is acutely ill or febrile (temperature ≥38.0 degree Celsius [°C]/100.4 degree Fahrenheit [°F]) less than 72 hours prior to or at the screening visit or Day 1.
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  • Has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to screening (for corticosteroids ≥10 milligrams [mg]/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Has received or plans to receive any licensed vaccine ≤28 days prior to the injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after the study injection, with the exception of influenza vaccines, which may be given 14 days before or after receipt of a study vaccine.
  • Has received systemic immunoglobulins or blood products within 3 months prior to the screening visit, or plans to receive these during the study.
  • Has donated ≥ 450 milliliters (mL) of blood products within 28 days prior to the screening visit or plans to donate blood products during the study.
  • Plans to participate in an interventional clinical trial of an investigational vaccine or drug while participating in this study.

Note: Other inclusion and exclusion criteria may apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05137236


Locations
Show Show 17 study locations
Sponsors and Collaborators
ModernaTX, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: ModernaTX, Inc.
ClinicalTrials.gov Identifier: NCT05137236    
Other Study ID Numbers: mRNA-1283-P201
First Posted: November 30, 2021    Key Record Dates
Last Update Posted: March 21, 2024
Last Verified: March 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ModernaTX, Inc.:
mRNA-1273
mRNA-1273 vaccine
SARS-CoV-2
SARS-CoV-2 Vaccine
Coronavirus
 Virus Diseases
Messenger RNA
COVID-19
COVID-19 Vaccine
Moderna